Aom0765

Aom0765 is a water-soluble, short-acting small molecule intravenous anesthetic being developed by Hangzhou Adamerck Pharmlabs. Currently in the preclinical stage, it is designed for use in general anesthesia as a potential alternative to established agents such as midazolam, remimazolam, and propofol. The candidate is engineered to offer superior pharmacological properties compared to existing anesthetics, including improved solubility and a favorable pharmacokinetic profile for rapid onset and recovery. While its specific molecular target has not been explicitly disclosed, it is positioned as a next-generation anesthetic candidate within the developer's pipeline.